Emergence of Candida albicans fungemia during voriconazole therapy

Abstract

Nowadays, the primary choice of therapy for infections due to Candida species is still fluconazole.1,2 However, several reports describing in vitro and clinical resistance to fluconazole developing during azole therapy have been published in the last years.3,4 This concern have resulted in the continued search for new agents with increased potency against Candida. Voriconazole, a second-generation triazole, have demonstrated excellent potency and broad-spectrum activity against all Candida species either in vitro5 and in vivo.